Patents by Inventor Olivier Civelli
Olivier Civelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6277591Abstract: A mammalian D2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: August 21, 2001Assignee: Oregon Health Science UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Publication number: 20010010919Abstract: The present invention relates to a novel mammalian anti-opioid receptor protein (OFQR), peptide ligands (such as OFQ) that bind to OFQR, and methods of using the OFQ peptide and analogues to reverse the physiologic effects of opiates such as morphine. The isolation, characterization and pharmacological use of the endogenous peptide ligand is described. A particular embodiment of the OFQ peptide is a heptadecapeptide having an FGGF aminoterminal motif. The peptide specifically binds to an OFQ receptor protein heterologously expressed in mammalian cells. The peptide does not bind with high affinity to &mgr;, &dgr; or &kgr; receptors, but it antagonizes opioid mediated effects (such as analgesia and hypothermia) without increasing nociceptive sensitivity. Tyrosine substitution variants of the peptide ligand specifically bind to the opioid receptor and can be radioiodinated.Type: ApplicationFiled: October 13, 1998Publication date: August 2, 2001Inventors: DAVID K. GRANDY, JUDITH E. GRISEL, JEFFREY S. MOGIL, JAMES R. BUNZOW, OLIVIER CIVELLI, RAINER KLAUS REINSCHEID, HANS-PETER NOTHACKER, FREDERICK MONSMA
-
Patent number: 6203998Abstract: The present invention is directed toward isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variant thereof are provided by the invention. The invention also includes recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize the human D4 dopamine receptor, and methods for characterizing novel psychotropic compounds using such cultures.Type: GrantFiled: April 15, 1998Date of Patent: March 20, 2001Assignee: Oregon Health Sciences Univ.Inventors: Olivier Civelli, Hubert Henri-Marie Van Tol
-
Patent number: 6028175Abstract: The present invention relates to a novel mammalian methadone-specific opioid receptor protein and genes that encode such a protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue of the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: October 13, 1998Date of Patent: February 22, 2000Assignee: Oregon Health Science UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 5883226Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variant thereof are provided by the invention. The invention also includes recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize the human D4 dopamine receptor, and methods for characterizing novel psychotropic compounds using such cultures.Type: GrantFiled: June 7, 1995Date of Patent: March 16, 1999Assignee: State of OregonInventors: Olivier Civelli, Hubert Henri-Marie Van Tol
-
Patent number: 5880260Abstract: A mammalian D.sub.2 dopamine receptor gene has been cloned. Thus, DNA sequences encoding all or a part of the dopamine receptor are provided, as well as the corresponding polypeptide sequences and methods for producing the same both synthetically and via expression of a corresponding sequence from a host transformed with a suitable vector carrying the corresponding DNA sequence. The various structural information provided by this invention enables the preparation of labeled or unlabeled immunospecific species, particularly antibodies, as well as nucleic acid probes labeled in conventional fashion. Pharmaceutical compositions and methods of using various products of this invention are also provided.Type: GrantFiled: June 7, 1995Date of Patent: March 9, 1999Assignee: Oregon Health Sciences UniversityInventors: Olivier Civelli, James R. Bunzow, David K. Grandy, Curtis A. Machida
-
Patent number: 5837809Abstract: The present invention relates to a novel mammalian opioid receptor protein and ligands that bind to such proteins. The invention is directed toward the isolation, characterization and pharmacological use of an endogenous ligand that specifically binds to a novel mammalian opioid receptor protein heterologously expressed in mammalian cells. The invention specifically provides the isolated peptide ligand and analogues, derivatives and variants thereof. The invention specifically provides tyrosine substitution variants of the peptide ligand that specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.Type: GrantFiled: August 11, 1995Date of Patent: November 17, 1998Assignee: Oregon Health Sciences UniversityInventors: David K. Grandy, James R. Bunzow, Olivier Civelli, Rainer Klaus Reinscheid, Hans-Peter Nothacker, Frederick James Monsma
-
Patent number: 5821067Abstract: The present invention relates to a novel mammalian met one-specific opioid receptor protein and genes that encode a such protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue or the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: August 15, 1997Date of Patent: October 13, 1998Assignee: State of OregonInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 5686573Abstract: The present invention relates to the isolation, characterization and pharmacological uses for the human D5 dopamine receptor, the gene corresponding to this receptor, pseudogenes of this receptor gene, a recombinant eukaryotic expression vector capable of expressing the human D5 dopamine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize the human D5 dopamine receptor. The invention relates to the biochemical and physiological characterization of the human D5 dopamine receptor and the development and testing of drugs useful for treating or preventing human disease.Type: GrantFiled: February 6, 1995Date of Patent: November 11, 1997Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences University, a non-profit organizationInventors: Olivier Civelli, David K. Grandy
-
Patent number: 5658783Abstract: The present invention relates to a novel mammalian methadone-specific opioid receptor protein and genes that encode a such protein. The invention is directed toward the isolation, characterization and pharmacological use of mammalian methadone-specific opioid receptor proteins. The invention specifically provides isolated complementary DNA copies of mRNA corresponding to the rat homologue or the mammalian methadone-specific opioid receptor gene. Also provided are recombinant expression constructs capable of expressing the mammalian methadone-specific opioid receptor genes of the invention in cultures of transformed prokaryotic and eukaryotic cells, as well as such cultures of transformed cells that synthesize the mammalian methadone-specific opioid receptor proteins encoded therein.Type: GrantFiled: November 8, 1993Date of Patent: August 19, 1997Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences University, a non-profit organizationInventors: David K. Grandy, James R. Bunzow, Olivier Civelli
-
Patent number: 5594108Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D.sub.4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor is provided by the invention. The invention also includes a recombinant eukaryotic expression vector capable of expressing the human D.sub.4 dopamine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells which synthesize the human D.sub.4 dopamine receptor.Type: GrantFiled: November 3, 1994Date of Patent: January 14, 1997Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventors: Olivier Civelli, Hubert H. Van Tol
-
Patent number: 5569601Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variant thereof are provided by the invention. The invention also includes recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize the human D4 dopamine receptor, and methods for characterizing novel psychotropic compounds using such cultures.Type: GrantFiled: August 10, 1992Date of Patent: October 29, 1996Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventor: Olivier Civelli
-
Patent number: 5547845Abstract: Cloned genes which code for the D.sub.1 dopamine receptor are disclosed. The receptors coded for by these clones bind dopamine ligands with the proper pharmacological profile and, when expressed in the cell membrane of a suitable host and so bound, stimulate adenylyl cyclase. Also disclosed are vectors comprising a cloned gene encoding a D.sub.1 -dopamine receptor, cells transformed with such vectors, and oligonucleotide probes capable of selectively hybridizing to DNA comprising a portion of a gene coding for a D.sub.1 -dopamine receptor. The cloned genes are useful for making proteins and cell membrane preparations which can be used to screen compounds for D.sub.1 -dopamine receptor binding activity, are useful in molecular biology, and are useful as diagnostic probes.Type: GrantFiled: February 15, 1994Date of Patent: August 20, 1996Assignees: Duke University, Oregon Health Sciences Univ.Inventors: James R. Bunzow, Olivier Civelli, David K. Grandy, Qun Y. Zhou
-
Patent number: 5516683Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variants thereof are provided by the invention. The invention particularly provides recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor at useful levels in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize such useful amounts of human D4 dopamine receptor protein, and methods for characterizing novel psychotropic compounds using such cultures.Type: GrantFiled: April 29, 1993Date of Patent: May 14, 1996Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences University a non-profit organizationInventors: David K. Grandy, James R. Bunzow, Olivier Civelli, Hubert H.-M. Van Tol
-
Patent number: 5441883Abstract: The present invention relates to a novel mammalian adenosine receptor. The invention is directed toward the isolation, characterization and pharmacological use of the rat A3 adenosine receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing the rat A3 adenosine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize the rat A3 adenosine receptor. The invention also provides methods for screening adenosine-receptor agonists and antagonists in vitro using preparations of the rat A3 adenosine receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the rat A3 adenosine receptor gene.Type: GrantFiled: August 2, 1993Date of Patent: August 15, 1995Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventors: Olivier Civelli, Qun-Yong Zhou
-
Patent number: 5427942Abstract: The present invention relates to the isolation, characterization and pharmacological uses for the human D5 dopamine receptor, the gene corresponding to this receptor, pseudogenes of this receptor gene, a recombinant eukaryotic expression vector capable of expressing the human D5 dopamine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize the human D5 dopamine receptor. The invention relates to the biochemical and physiological characterization of the human D5 dopamine receptor and the development and testing of drugs useful for treating or preventing human disease.Type: GrantFiled: November 13, 1991Date of Patent: June 27, 1995Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventors: Olivier Civelli, David K. Grandy
-
Patent number: 5422265Abstract: The present invention is directed toward the human D.sub.4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor is provided by the invention. The invention also includes a recombinant eukaryotic expression vector capable of expressing the human D.sub.4 dopamine receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells which synthesize the human D.sub.4 dopamine receptor.Type: GrantFiled: December 7, 1990Date of Patent: June 6, 1995Assignee: State of Oregon, Acting by and Through the State Board of Higher Education on Behalf of the Oregon Health Sciences UniversityInventors: Olivier Civelli, Hubert H. Van Tol
-
Patent number: 5389543Abstract: Cloned genes which code for the D.sub.1 dopamine receptor are disclosed. The receptors coded for by these clones bind dopamine ligands with the proper pharmacological profile and, when expressed in the cell membrane of a suitable host and so bound, stimulate adenylyl cyclase. Also disclosed are vectors comprising a cloned gene encoding a D.sub.1 -dopamine receptor, cells transformed with such vectors, and oligonucleotide probes capable of selectively hybridizing to DNA comprising a portion of a gene coding for a D.sub.1 -dopamine receptor. The cloned genes are useful for making proteins and cell membrane preparations which can be used to screen compounds for D.sub.1 -dopamine receptor binding activity, are useful in molecular biology, and are useful as diagnostic probes.Type: GrantFiled: July 2, 1992Date of Patent: February 14, 1995Assignees: Duke University, Oregon Health Sciences UniversityInventors: James R. Bunzow, Olivier Civelli, David K. Grandy, Qun Y. Zhou, Marc G. Caron, Allen Dearry, Pierre Falardeau, Jay A. Gingrich